MAGEH1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9H213 |
---|---|
Clone Names | 2091604 |
Gene ID | 28986 |
---|---|
Other Names | Melanoma-associated antigen H1, Apoptosis-related protein 1, APR-1, MAGE-H1 antigen, Restin, MAGEH1, APR1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6180a was selected from the C-term region of human MAGEH1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | MAGEH1 |
---|---|
Synonyms | APR1 |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Melanoma-associated antigen (MAGE) are completely silent in normal tissues, with the exception of male germ cells, and, for some of them, placenta. These antigens ought to be strictly tumor specific, expressed in tumor cells of various histological types. Because of their specific expression on tumor cells, these antigens are of particular interest for antitumor immunotherapy. Genes of the MAGE family direct the expression of tumor antigens that are recognized on a human melanoma by autologous cytolytic T lymphocytes. Though the function of MAGEH1 is not fully elucidated, it may play a role in embryonal development and tumor transformation or aspects of tumor progression.
References
Chomez, P., et al., Cancer Res. 61(14):5544-5551 (2001).Zhu, F., et al., BioTechniques 29(2):310-313 (2000).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.